Equities research analysts expect Regenxbio Inc (NASDAQ:RGNX) to post ($0.71) earnings per share for the current quarter, Zacks reports. Zero analysts have made estimates for Regenxbio’s earnings, with the lowest EPS estimate coming in at ($0.75) and the highest estimate coming in at ($0.67). Regenxbio reported earnings per share of ($0.74) in the same quarter last year, which would suggest a positive year over year growth rate of 4.1%. The company is scheduled to report its next quarterly earnings report on Tuesday, March 6th.
According to Zacks, analysts expect that Regenxbio will report full year earnings of ($2.71) per share for the current financial year, with EPS estimates ranging from ($2.87) to ($2.43). For the next year, analysts forecast that the firm will post earnings of ($3.02) per share, with EPS estimates ranging from ($3.21) to ($2.73). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Regenxbio.
Regenxbio (NASDAQ:RGNX) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.67) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.71) by $0.04. Regenxbio had a negative return on equity of 39.33% and a negative net margin of 764.06%. The business had revenue of $1.34 million during the quarter.
Several research analysts recently weighed in on RGNX shares. Chardan Capital reaffirmed a “buy” rating and set a $75.00 target price (up previously from $55.00) on shares of Regenxbio in a research note on Tuesday, September 5th. Zacks Investment Research raised Regenxbio from a “hold” rating to a “strong-buy” rating and set a $38.00 target price for the company in a research note on Wednesday, October 18th. Morgan Stanley reaffirmed an “overweight” rating and set a $34.00 target price on shares of Regenxbio in a research note on Thursday, November 9th. Barclays started coverage on Regenxbio in a research note on Wednesday, November 22nd. They set an “overweight” rating and a $38.00 target price for the company. Finally, Bank of America reaffirmed a “buy” rating and set a $38.00 target price (up previously from $33.00) on shares of Regenxbio in a research note on Monday, October 9th. One analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the stock. Regenxbio currently has a consensus rating of “Buy” and a consensus target price of $42.43.
Shares of Regenxbio (RGNX) remained flat at $$28.15 during mid-day trading on Friday. 188,900 shares of the stock were exchanged, compared to its average volume of 279,474. Regenxbio has a 1 year low of $16.30 and a 1 year high of $36.10.
In other news, insider Kenneth T. Mills sold 10,000 shares of the company’s stock in a transaction on Wednesday, September 20th. The stock was sold at an average price of $29.33, for a total transaction of $293,300.00. Following the completion of the sale, the insider now directly owns 108,630 shares of the company’s stock, valued at $3,186,117.90. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director Donald J. Hayden, Jr. sold 40,000 shares of the company’s stock in a transaction on Monday, September 18th. The shares were sold at an average price of $28.70, for a total value of $1,148,000.00. Following the sale, the director now directly owns 20,000 shares of the company’s stock, valued at $574,000. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 139,000 shares of company stock valued at $4,278,346. 17.00% of the stock is currently owned by company insiders.
Institutional investors have recently made changes to their positions in the stock. Legal & General Group Plc lifted its stake in Regenxbio by 41.4% in the 2nd quarter. Legal & General Group Plc now owns 6,870 shares of the biotechnology company’s stock worth $137,000 after acquiring an additional 2,011 shares in the last quarter. Ardsley Advisory Partners purchased a new stake in Regenxbio in the 2nd quarter worth about $197,000. Voya Investment Management LLC purchased a new stake in Regenxbio in the 2nd quarter worth about $249,000. Asymmetry Capital Management L.P. lifted its stake in Regenxbio by 12.2% in the 2nd quarter. Asymmetry Capital Management L.P. now owns 13,906 shares of the biotechnology company’s stock worth $275,000 after acquiring an additional 1,508 shares in the last quarter. Finally, Wells Fargo & Company MN lifted its stake in Regenxbio by 1.1% in the 2nd quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock worth $320,000 after acquiring an additional 175 shares in the last quarter. 68.73% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: “Analysts Expect Regenxbio Inc (RGNX) to Announce -$0.71 Earnings Per Share” was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.dispatchtribunal.com/2017/12/15/analysts-expect-regenxbio-inc-rgnx-to-announce-0-71-earnings-per-share.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Get a free copy of the Zacks research report on Regenxbio (RGNX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.